The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.

• Status: Unknown status
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McGill University Health Center; McGill University Health Centre/Research Institute of the McGill University Health Centre
• Collaborator: Merck Frosst Canada Ltd.
• Treatments: Alendronate

Criteria

Inclusion Criteria:

Male and Female aged > 55 Low trauma hip fracture up to 90 days Be willing to submit to periodic bone mineral density radiographic studies of the spine & 24 hr urine collection Written informed consent

-

Exclusion Criteria:

• Disorders known to affect bone metabolism Not taking bisphosphonates within last 6 months Drugs known to interfere with calcium metabolism within the lats 6 months prior to hip fracture serum calcium> 2.65 mmol/L Treatment with any investigational drug within the last 30 days